Skip to main content
OpenTrials
Completed

NCT Number: NCT00329914

Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?

The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Graz University Hospital, Graz, Austria

Loading trial locations.

About this study

Multiple gestations account for 2% of all pregnancies, but cause more than 10% of the cases of preterm delivery. Due to increasing maternal age and use of assisted reproduction the number of multiple gestations is larger than ever. If markers of preterm delivery can be identified and means of preventing preterm delivery are found, it will be possible to reduce the number of children admitted to hospital because of prematurity.

Recently, two larger randomised studies investigated the effect of progesterone in singleton pregnancies of women who had previously delivered preterm. They both found a significant reduction in the preterm delivery rate in the progesterone group compared to a placebo group.

The study will be performed as a randomized, double-blind placebo controlled study of twin pregnancies in Denmark and Austria. The women will be randomised in a 1:1 ratio to two groups (progesterone versus placebo). Randomisation will be stratified per centre and according to chorionicity, as the risk of preterm delivery is doubled in monochorionic twins compared to dichorionic twins.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Twin pregnancy
  • Informed consent
  • 18-23 weeks' gestation
  • Participants must be fluent in the language spoken in the respective centres

Exclusion criteria

  • Age < 18 years
  • Known allergy to progesterone or peanuts
  • Active thromboembolic disorders or a history of hormone-associated thromboembolic disorders
  • Rupture of membranes at the time of inclusion
  • Monoamniotic twins
  • Pregnancies treated for or with signs of twin-to-twin transfusion syndrome at inclusion
  • Multiple pregnancies reduced to twin pregnancies
  • Known significant structural or chromosomal fetal abnormality
  • Chorionicity not assessed before 15 weeks
  • Known or suspected malignancy in genitals or breasts
  • Known liver disease

Treatment and study plan

Progesterone

Drug

Vaginal pessaries, 200 mg/day

Other names: Utrogestan

Placebo

Drug

Placebo pessaries containing peanut oil

Primary outcomes

  1. The incidence of delivery < 34 weeks, in the study group versus the control group

    Time frame: Participants will be followed until 3 weeks after delivery

Secondary outcomes

  1. Physical and neurological development of the children at 6 and 18 months

    Time frame: 2 years after delivery

  2. The relationship between cervical length and prophylactic progesterone treatment

    Time frame: Participants will be followed until 3 weeks after delivery

  3. Determination of proteomics and RNA in preterm delivery and term delivery and an evaluation of the effect of progesterone on proteomics and RNA

    Time frame: Participants will be followed until 3 weeks after delivery

  4. Assessment of the potential anti-inflammatory effect of progesterone by cytokine-measurements

    Time frame: Participants will be followed until 3 weeks after delivery

  5. Assessment of the effect of progesterone on CRH-levels in twin pregnancies

    Time frame: Participants will be followed until 3 weeks after delivery

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • AP Moeller Foundation
  • The Danish Medical Research Council
  • The Danish Medical Society in Copenhagen

Registry information

Official study title

Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial

Important dates

Study start
2006
Primary completion
2009
Study completion
2010
First posted
May 25, 2006
Registry last updated
Jul 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.